ERα and its cognate ligand oestrogen are the major drivers of tumour development and disease progression in luminal breast cancers, and agents that impair ER signalling in ER-positive breast cancers represent highly successful targeted therapies that are widely used in both early breast cancer, as well as the metastatic setting2. This evidence concerns the gene ESR1 and breast carcinoma.